Files

729774.pdf (314.22 KB)

Document type

Article

Version

Published version

Publication date

2022-11-06

Publication license

cc-by (c) Saponaro, Mariarosaria et al., 2022
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/193597

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.3390/ijms232113604

Abstract

In patients with early-stage endocrine receptor-positive (ER+) breast cancer (BC), adjuvant endocrine therapy (ET) for 5 years is the standard of care. However, for some patients, the risk of recurrence remain high for up to 15 years after diagnosis and extended ET beyond 5 years may be a reasonable option. Nevertheless, this strategy significantly increases the occurrence of side effects. Here we summarize the available evidence from randomized clinical trials on the efficacy and safety profile of extended ET and discuss available clinical and genomic tools helpful to select eligible patients in daily clinical practice.

Subject

Càncer de mama, Tractament adjuvant del càncer, Hormonoteràpia, Receptors d'hormones, Genòmica, Efectes secundaris

Subject (English)

Breast cancer, Adjuvant treatment of cancer, Hormone therapy, Hormone receptors, Genomics, Side effects

Citation

Collections

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citation

SAPONARO, Mariarosaria, et al. Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests. International Journal of Molecular Sciences. 2022. Vol. 23, num. 21, pags. 13604. ISSN 1661-6596. [consulted: 16 of June of 2026]. Available at: https://hdl.handle.net/2445/193597

Export metadata

JSON - METS

Share record